Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|July 5, 2017
FDA Pushes DSCSA Serialization Enforcement Deadline to 2018
Author(s)Pharmaceutical Technology Editors
The agency has pushed back by one year the deadline for compliance with DSCSA serialization requirements.
Advertisement
On June 30, 2017, FDA published
Noting the fact that some pharmaceutical manufacturers still have not installed the technologies required, and acknowledging the limited number of vendors capable of offering solutions, as well as lack of readiness among contract manufacturers, FDA is now giving pharma companies until Nov. 26, 2018 to meet requirements.
This year, a number of surveys had shown that a significant number of small-to-mid-sized pharma companies were still not ready for serialization requirements required by DSCSA and the Nov. 27, 2017 compliance deadline. This additional time should allow them more time to examine the scope of work required and evaluate the best solutions.
Source:
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Advertisement
Advertisement